PsychoactiveMap

Adams Clinical Harlem psychedelic research trials

Data as of 31 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.

Adams Clinical Harlem is listed with 5 registered studies counted here, in New York, United States. By compound: 3 psilocybin and 2 LSD. By registry status: 1 recruiting, 1 enrolling by invitation, 2 active, not recruiting and 1 completed. By phase: 5 phase 3. Reported start years run from 2024 (earliest) to 2025 (latest).

Institution name, city and country are copied from the research site linked to each registry record. A study counts once per institution, and a study tagged with more than one compound is counted under each compound.

Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.

At a glance

By compound

Compound hubStudies
Psilocybin3
LSD2

By registry status

StatusStudiesShare
Recruiting120%
Enrolling by invitation120%
Active, not recruiting240%
Completed120%

By phase

PhaseStudiesShare
Phase 35100%

Registered studies

All counted studies, newest start first. Dates may be estimated, including future dates; a listed date does not confirm that a study started. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.

Title as registeredRegistry IDStatusPhaseRegistry datesCompound
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive DisorderNCT06793397RecruitingPhase 3Source start: 2025-12-10 (actual)
Source date details

Start: 2025-12-10 (precision: day; source type: ACTUAL; actual)

Primary completion: 2027-06-07 (precision: day; source type: ESTIMATED; estimated)

Study completion: 2027-08-09 (precision: day; source type: ESTIMATED; estimated)

Observation retrieved: 2026-10-31T20:06:17.780Z; registry revision: 2026-10-30 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred.

Psilocybin
Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)NCT06605105Enrolling by invitationPhase 3Source start: 2025-07-18 (actual)
Source date details

Start: 2025-07-18 (precision: day; source type: ACTUAL; actual)

Primary completion: 2028-06-06 (precision: day; source type: ESTIMATED; estimated)

Study completion: 2028-06-06 (precision: day; source type: ESTIMATED; estimated)

Observation retrieved: 2026-10-31T20:06:17.720Z; registry revision: 2026-09-25 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred.

Psilocybin
A Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge)NCT06941844Active, not recruitingPhase 3Source start: 2025-04-14 (actual)
Source date details

Start: 2025-04-14 (precision: day; source type: ACTUAL; actual)

Primary completion: 2026-05-20 (precision: day; source type: ACTUAL; actual)

Study completion: 2027-02 (precision: month; source type: ESTIMATED; estimated)

Observation retrieved: 2026-10-31T20:06:18.089Z; registry revision: 2026-08-28 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred.

LSD
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"NCT06564818CompletedPhase 3Source start: 2024-12-17 (actual)
Source date details

Start: 2024-12-17 (precision: day; source type: ACTUAL; actual)

Primary completion: 2026-09-04 (precision: day; source type: ACTUAL; actual)

Study completion: 2026-10-23 (precision: day; source type: ACTUAL; actual)

Observation retrieved: 2026-10-31T20:06:17.400Z; registry revision: 2026-10-27 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred.

Psilocybin
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage)NCT06741228Active, not recruitingPhase 3Source start: 2024-12-11 (actual)
Source date details

Start: 2024-12-11 (precision: day; source type: ACTUAL; actual)

Primary completion: 2026-07-15 (precision: day; source type: ACTUAL; actual)

Study completion: 2027-04 (precision: month; source type: ESTIMATED; estimated)

Observation retrieved: 2026-10-31T20:06:17.720Z; registry revision: 2026-09-25 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred.

LSD

About this data

Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.

Substance hubs for these compounds

Psilocybin | LSD

Country hub: United States

All trial hubs | Learn | Disclaimer